RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Interdisciplinary intervention for COPD - Chronic Obstructive Pulmonary Disease

Introduction: Pulmonary rehabilitation programs (PRPs) are known to reduce symptoms such as dyspnea and fatigue, while improving functional capacity and quality of life in individuals with chronic obstructive pulmonary disease (COPD). However, the benefits of an initial pulmonary rehabilitation program (PRP) tend to diminish rapidly over time, prompting the development of strategies to maintain these effects.

Official registry: https://clinicaltrials.gov/study/NCT07394712 · Institut de Recerca Biomèdica de Lleida · enrollment listed as 86

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Interdisciplinary intervention. The registry lists allocation as randomized. Introduction: Pulmonary rehabilitation programs (PRPs) are known to reduce symptoms such as dyspnea and fatigue, while improving functional capacity and quality of life in individuals with chronic obstructive pulmonary disease (COPD).

They plan to enroll about 86 people at 2 sites. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.

Official title (unrewritten)

Comprehensive Maintenance Program: a Health Haven for COPD in Lleida.The NAPOLEON Project.

Interventions: Interdisciplinary intervention

Primary outcome (registry wording): Dyspnea (Dyspnea-12 total score)

Who it is for (from inclusion criteria)

Ages 40 Years to 75 Years
Adults aged 40 to 75 years
Confirmed medical diagnosis of chronic obstructive pulmonary disease (COPD) of moderate to severe severity, based on clinical evaluation and pulmonary function testing
Clinically stable for at least 4 weeks following the last severe exacerbation, as confirmed by the treating pulmonologist
Referred to an outpatient pulmonary rehabilitation program due to persistent symptoms and a history of exacerbations, with moderate to severe dyspnea (Medical Research Council \[MRC\] dyspnea scale score \> 2), according to physician assessment
Completed at least 6 out of 8 sessions of a standard 8-week initial pulmonary rehabilitation program

Who the registry excludes

Severe cognitive impairment that limits the ability to understand instructions or participate actively in the program
Unstable psychiatric disorders that may compromise adherence to or continuity with the exercise regimen
Lack of availability or refusal to attend the scheduled sessions of the community-based exercise program
Participation in another pulmonary rehabilitation program within the 6 months prior to study enrollment

Public study contact (from the registry)

Jessica G MD, PhD, MD, PhD

973702497

jgonzalezgutierrez88@gmail.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

2 listed

Arnau de Vilanova University Hospital — Lleida, Catalonia, Spain (recruiting)
Arnau de Vilanova University Hospital — Lleida, Lleida, Spain (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Re…

We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.

NCT00001238 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT07394712 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07394712?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07394712?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary